J.P. Morgan initiates coverage of Aktis Oncology with 'overweight' rating

Aktis Oncology

03/02/2026 16:01

** J.P. Morgan initiates coverage of Aktis Oncology AKTS.O with "overweight" rating; sets PT of $30

** Brokerage lauds cancer drug developer's platform for developing radiopharmaceutical therapies, which are a novel means of delivering targeted radiation for cancer

** "We see the RPT modality taking off in the coming years and see Aktis entering at a sweet spot where it can both leverage past learnings in the space while also being early enough to be positioned to develop first-in-class products in a relatively open field," says JPM

** Including session's move, AKTS is down 20.9% since its debut on January 9

(Reporting by Pragyan Kalita in Bengaluru)

((Pragyan.Kalita@thomsonreuters.com))